CPAP treatment after atrial fibrillation ablation in people with obstructive sleep apnea
Tests CPAP in people with sleep apnea after atrial fibrillation ablation.
Plain-language title generated from the registry record
Registry title: Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
Key facts
- Where
- Beijing, Changchun, Changsha, Dalian, Dongying, Fuzhou, Harbin, Kunming, Langfang, Linyi, Nanjing, Nanning, Ningbo, Shangqiu, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xingtai, Zhangzhou, and Zhengzhou, ChinaSee the 30 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07444372, who can take part
Where in China
- Beijing Anzhen HospitalBeijing, ChinaTaking people
- Beijing Chaoyang Hospital, Capital Medical UniversityBeijing, ChinaNot yet recruiting
- Beijing HospitalBeijing, ChinaNot yet recruiting
- Beijing Jishuitan HospitalBeijing, ChinaNot yet recruiting
- Peking University International HospitalBeijing, ChinaNot yet recruiting
- The First Hospital of Jilin UniversityChangchun, ChinaNot yet recruiting
- The Second Xiangya Hospital of Central South UniversityChangsha, ChinaNot yet recruiting
- First Affiliated Hospital of Dalian Medical UniversityDalian, ChinaNot yet recruiting
- Shengli Oilfield Central HospitalDongying, ChinaNot yet recruiting
- First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaNot yet recruiting
- Fujian Medical University Union HospitalFuzhou, ChinaNot yet recruiting
- Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNot yet recruiting
- Yan'an Hospital of Kunming CityKunming, ChinaNot yet recruiting
- Langfang People's HospitalLangfang, ChinaNot yet recruiting
- Linyi People's HospitalLinyi, ChinaNot yet recruiting
- The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaNot yet recruiting
- People's Hospital of Guangxi Zhuang Autonomous RegionNanning, ChinaNot yet recruiting
- First Affiliated Hospital of Ningbo UniversityNingbo, ChinaNot yet recruiting
- Shangqiu First People's HospitalShangqiu, ChinaNot yet recruiting
- First Affiliated Hospital of China Medical UniversityShenyang, ChinaNot yet recruiting
- Shengjing Hospital Of China Medical UniversityShenyang, ChinaNot yet recruiting
- Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western MedicineShijiazhuang, ChinaTaking people
- Second hospital of Shanxi Medical UniversityTaiyuan, ChinaNot yet recruiting
- Tianjin Chest HospitalTianjin, ChinaNot yet recruiting
- Tianjin Medical University Second HospitalTianjin, ChinaNot yet recruiting
- Wuhan Asia General HospitalWuhan, ChinaNot yet recruiting
- Wuhan NO.1 HospitalWuhan, ChinaNot yet recruiting
- The Ninth Hospital of XingtaiXingtai, ChinaTaking people
- Zhangzhou Hospital of Fujian ProvinceZhangzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT07444372
- Record updated
- 5 October 2026
- Original description
Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.Read full original descriptionShow less
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation: A Multicenter, Open-label, Randomized Clinical Trial
Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.
This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.
Participants will:
* Be randomly assigned to either the CPAP group or the usual care group. * If in the CPAP group, use a CPAP device for 12 months. * Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization. * Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.
Inclusion: Patients must meet all of the following conditions to be eligible for the study:; Age 18-75 years; Patients with persistent AF who received catheter ablation for the first time; Diagnosed with OSA; Able to tolerate CPAP therapy; Capable of understanding and complying with the study protocol; Willing to sign the informed consent form.
Exclusion: History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening; History of stroke or transient ischemic attack within 6 months prior to screening; Perioperative complications related to the ablation procedure occurring prior to randomization; Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons; Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization; Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery; Current participation in other drug or device trials; Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic); Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with > 1 episode of respiratory failure or hypercapnia; Left ventricular ejection fraction < 30%; Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year; Patients meeting any of the following criteria will be excluded from the study:; Secondary AF; Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view); Pregnant or breastfeeding women; Life expectancy < 1 year; Central sleep apnea.